Parmar, Mona
Institute of Cancer Research
4 papers on CoChatORCID 0000-0001-7818-4100
Most cited papers
- Verified
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology
Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling
Cited by 78
- Verified
725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer
Banerjee, S., Grochot, R., Shinde, R., Lima, J., Krebs, M., Rahman, R., Little, M., Tunariu, N., Curcean, A., Badham, H., et al. (2021) · Annals of Oncology
Ovarian cancer diagnosis and treatmentOvarian function and disorders
Cited by 17
- Verified
Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., et al. (2021) · Cancer Research
Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways
Cited by 10
- Verified
Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response
Stewart, A. R., Pickard, L., Paranjape, E., Perez, V. S., Chowdhury, S., Lustgarten, S., Coma, S., Pachter, J. A., Carey, M. S., DiMattia, G., et al. (2022) · Cancer Research
Ovarian cancer diagnosis and treatmentMelanoma and MAPK Pathways
Cited by 1
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free